Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and pharmacy experts are reacting to last…
Read More
"Patients with DPYD variations are 25.6X more likely to experience treatment related death on standard‐dose fluoropyrimidine chemotherapy (5‐fluorouracil or capecitabine)." - Kristine Ashcraft, President and Founder of YouScript Read more about…
Read More
The association between variants of the DPYD gene and serious side effects from the cancer drug 5-fluorouracil (5–FU) in colon cancer patients has been bolstered by the results of recent…
Read More
